\-\ Texto\\:\\ \ \(0\)\
\-\ left\\-sided\\ foot\\ drop\\.\ \(0\)\
\-\ patient\\ underwent\\ resection\\ of\\ the\\ mass\\ and\\ is\\ being\\ treated\\ with\\ phenytoin\\ for\\ seizure\\ prophylaxis\\.\\ \\ the\\ patient\\ has\\ had\\ a\\ follow\\ up\\ mri\\ to\\ assess\\ for\\ residual\\ tumor\\.\ \(0\)\
\-\ noncontrast\\ head\\ ct\\ demonstrates\\ a\\ large\\ right\\ temporal\\ mass\\ with\\ subfalcine\\ and\\ uncal\\ herniation\\ from\\ right\\ to\\ left\\.\\ \\ the\\ mass\\ is\\ heterogenous\\ with\\ several\\ curvilinear\\ areas\\ of\\ calcification\\ and\\ surrounding\\ vasogenic\\ edema\\.\\ \\ \ \(0\)\
\-\ the\\ mri\\ images\\ again\\ demonstrate\\ signal\\ heterogenity\\ with\\ partial\\ central\\ necrosis\\.\\ \\ the\\ lesion\\ produces\\ moderate\\-to\\-severe\\ mass\\ effect\\ with\\ effacement\\ of\\ the\\ left\\ lateral\\ ventricle\\,\\ and\\ subfalcine\\ and\\ transtentorial\\ herniation\\.\ \(0\)\
\-\ glioblastoma\\ multiforme\ \(8\)\
\-\ astrocytoma\ \(206\)\
\-\ oligodendroglioma\ \(21\)\
\-\ metastastic\\ disease\\,\\ partially\\ hemorrhagic\\ lesion\ \(0\)\
\-\ primary\\ cns\\ lymphoma\ \(0\)\
\-\ 44\\-year\\ old\\ woman\\ with\\ several\\ week\\ history\\ of\\ headaches\\.\\ \\ patient\\ developed\\ a\\ left\\-sided\\ foot\\ drop\\ approximately\\ one\\-week\\ prior\\ to\\ presenting\\ to\\ her\\ physician\\.\ \(0\)\
\-\ glioblastoma\\ multiforme\\ is\\ the\\ most\\ common\\ primary\\ brain\\ tumor\\.\\ \\ approximately\\ 50\\%\\ of\\ astrocytomas\\ are\\ gbms\\.\\ \\ these\\ tumors\\ normally\\ occur\\ in\\ patients\\ over\\ 50\\.\\ \\ this\\ patient\\,\\ at\\ 44\\-years\\ old\\,\\ is\\ at\\ the\\ younger\\ end\\ of\\ the\\ age\\ spectrum\\.\ \(0\)\
\-\ these\\ lesions\\ are\\ varied\\ in\\ their\\ appearance\\ secondary\\ to\\ their\\ multiple\\ pathologic\\ forms\\.\\ \\ however\\,\\ they\\ typically\\ are\\ highly\\ vascular\\ with\\ edema\\ and\\ hemorrhage\\ being\\ common\\.\\ \\ they\\ demonstrate\\ strong\\,\\ heterogeneous\\ enhancement\\.\\ \\ calcification\\ is\\ rare\\,\\ although\\ this\\ lesion\\ did\\ demonstrate\\ several\\ areas\\ of\\ calcification\\.\ \(0\)\
\-\ this\\ lesion\\ does\\ not\\ cross\\ the\\ corpus\\ callosum\\,\\ although\\ it\\ is\\ one\\ of\\ two\\ intracranial\\ neoplasms\\,\\ along\\ with\\ primary\\ cns\\ lymphma\\,\\ that\\ can\\ extend\\ through\\ white\\ matter\\ tracts\\ and\\ involve\\ both\\ hemispheres\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ subfalcine\\:\\ 0\\.19731376743685622\ \(0\)\
\-\ drop\\:\\ 0\\.16504719446793234\ \(0\)\
\-\ calcification\\:\\ 0\\.16250013904388613\ \(0\)\
\-\ multiforme\\:\\ 0\\.15812362741582076\ \(0\)\
\-\ the\\:\\ 0\\.15138502992651798\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.1513157636377545\ \(0\)\
\-\ several\\:\\ 0\\.14933141964033336\ \(0\)\
\-\ lesion\\:\\ 0\\.14549207290162752\ \(0\)\
\-\ cns\\:\\ 0\\.1416997599588803\ \(0\)\
\-\ primary\\:\\ 0\\.13995271910427698\ \(0\)\
\-\ herniation\\:\\ 0\\.12763776932089915\ \(0\)\
\-\ their\\:\\ 0\\.12593204784521161\ \(0\)\
\-\ is\\:\\ 0\\.12466252766085656\ \(0\)\
\-\ heterogenity\\:\\ 0\\.12133015332815068\ \(0\)\
\-\ lymphma\\:\\ 0\\.12133015332815068\ \(0\)\
\-\ foot\\:\\ 0\\.11989745126890351\ \(0\)\
\-\ with\\:\\ 0\\.11884791351859887\ \(0\)\
\-\ of\\:\\ 0\\.11877694432266905\ \(0\)\
\-\ demonstrate\\:\\ 0\\.11832569844491549\ \(0\)\
\-\ metastastic\\:\\ 0\\.1159374388530164\ \(0\)\
\-\ mass\\:\\ 0\\.11591887612784216\ \(0\)\
\-\ to\\:\\ 0\\.11380176691810066\ \(0\)\
\-\ gbms\\:\\ 0\\.11211124704187418\ \(0\)\
\-\ and\\:\\ 0\\.10974099095446992\ \(0\)\
\-\ phenytoin\\:\\ 0\\.10914342210418806\ \(0\)\
\-\ they\\:\\ 0\\.1084188198129109\ \(0\)\
\-\ transtentorial\\:\\ 0\\.1067185325667399\ \(0\)\
\-\ 50\\:\\ 0\\.10596922441830935\ \(0\)\
\-\ being\\:\\ 0\\.10573622899494774\ \(0\)\
\-\ uncal\\:\\ 0\\.10466831767566107\ \(0\)\
\-\ left\\:\\ 0\\.10352151929019185\ \(0\)\
\-\ although\\:\\ 0\\.10329956220055131\ \(0\)\
\-\ areas\\:\\ 0\\.10301881932265626\ \(0\)\
\-\ week\\:\\ 0\\.1020589162750187\ \(0\)\
\-\ varied\\:\\ 0\\.09992451581791156\ \(0\)\
\-\ patient\\:\\ 0\\.09870478034474273\ \(0\)\
\-\ approximately\\:\\ 0\\.096819180508816\ \(0\)\
\-\ astrocytomas\\:\\ 0\\.09070560953163505\ \(0\)\
\-\ edema\\:\\ 0\\.09049920818879655\ \(0\)\
\-\ tracts\\:\\ 0\\.08884676586137195\ \(0\)\
\-\ one\\:\\ 0\\.0868764875352289\ \(0\)\
\-\ are\\:\\ 0\\.08636586833778832\ \(0\)\
\-\ common\\:\\ 0\\.08605219186484103\ \(0\)\
\-\ these\\:\\ 0\\.085685792948358\ \(0\)\
\-\ prophylaxis\\:\\ 0\\.08364821644602631\ \(0\)\
\-\ produces\\:\\ 0\\.08326268016542193\ \(0\)\
\-\ oligodendroglioma\\:\\ 0\\.07962785957509545\ \(0\)\
\-\ tumor\\:\\ 0\\.07936719269673012\ \(0\)\
\-\ younger\\:\\ 0\\.07934182553201483\ \(0\)\
\-\ forms\\:\\ 0\\.07906181370791038\ \(0\)\
\-\ strong\\:\\ 0\\.07906181370791038\ \(0\)\
\-\ curvilinear\\:\\ 0\\.07851887830767242\ \(0\)\
\-\ this\\:\\ 0\\.07820928753630131\ \(0\)\
\-\ mri\\:\\ 0\\.07788825130820554\ \(0\)\
\-\ spectrum\\:\\ 0\\.07701159881683155\ \(0\)\
\-\ cross\\:\\ 0\\.07565788181887725\ \(0\)\
\-\ effacement\\:\\ 0\\.07523562189676816\ \(0\)\
\-\ vasogenic\\:\\ 0\\.07462635184340208\ \(0\)\
\-\ hemispheres\\:\\ 0\\.07366909923277609\ \(0\)\
\-\ noncontrast\\:\\ 0\\.07330469094768967\ \(0\)\
\-\ heterogenous\\:\\ 0\\.07146148522206368\ \(0\)\
\-\ callosum\\:\\ 0\\.07146148522206368\ \(0\)\
\-\ neoplasms\\:\\ 0\\.07070127429508996\ \(0\)\
\-\ assess\\:\\ 0\\.07012291924573831\ \(0\)\
\-\ extend\\:\\ 0\\.06998217644685606\ \(0\)\
\-\ normally\\:\\ 0\\.06916763192072826\ \(0\)\
\-\ corpus\\:\\ 0\\.06916763192072826\ \(0\)\
\-\ residual\\:\\ 0\\.06903659568461551\ \(0\)\
\-\ highly\\:\\ 0\\.06791197647255537\ \(0\)\
\-\ again\\:\\ 0\\.06767446890428705\ \(0\)\
\-\ end\\:\\ 0\\.06676470782242902\ \(0\)\
\-\ involve\\:\\ 0\\.06676470782242902\ \(0\)\
\-\ physician\\:\\ 0\\.06654666899858945\ \(0\)\
\-\ hemorrhagic\\:\\ 0\\.06581050883835339\ \(0\)\
\-\ partially\\:\\ 0\\.06511296702463008\ \(0\)\
\-\ seizure\\:\\ 0\\.06313227696715193\ \(0\)\
\-\ pathologic\\:\\ 0\\.062164572434273604\ \(0\)\
\-\ intracranial\\:\\ 0\\.06104626105746646\ \(0\)\
\-\ presenting\\:\\ 0\\.05943215311773463\ \(0\)\
\-\ partial\\:\\ 0\\.05845556261801054\ \(0\)\
\-\ temporal\\:\\ 0\\.058280174532937684\ \(0\)\
\-\ necrosis\\:\\ 0\\.05799290482577092\ \(0\)\
\-\ matter\\:\\ 0\\.05776747450726017\ \(0\)\
\-\ at\\:\\ 0\\.05731294106273984\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.05727380697753703\ \(0\)\
\-\ rare\\:\\ 0\\.05727380697753703\ \(0\)\
\-\ headaches\\:\\ 0\\.05659160255207688\ \(0\)\
\-\ developed\\:\\ 0\\.05628816573205255\ \(0\)\
\-\ ventricle\\:\\ 0\\.055845608697949835\ \(0\)\
\-\ tumors\\:\\ 0\\.05579733252740814\ \(0\)\
\-\ occur\\:\\ 0\\.05579733252740814\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.05491188711650539\ \(0\)\
\-\ did\\:\\ 0\\.05442497492320471\ \(0\)\
\-\ typically\\:\\ 0\\.05326047541025483\ \(0\)\
\-\ effect\\:\\ 0\\.05322071433316294\ \(0\)\
\-\ does\\:\\ 0\\.05244947972517552\ \(0\)\
\-\ underwent\\:\\ 0\\.05226346172253695\ \(0\)\
\-\ along\\:\\ 0\\.05082895076646719\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.050795824795714775\ \(0\)\
\-\ central\\:\\ 0\\.050664139854791186\ \(0\)\
\-\ surrounding\\:\\ 0\\.0505987831120625\ \(0\)\
\-\ right\\:\\ 0\\.050307054441636655\ \(0\)\
\-\ vascular\\:\\ 0\\.05008717886973322\ \(0\)\
\-\ white\\:\\ 0\\.050055847711824544\ \(0\)\
\-\ resection\\:\\ 0\\.04863265746030429\ \(0\)\
\-\ age\\:\\ 0\\.04763095817437637\ \(0\)\
\-\ her\\:\\ 0\\.04739829794912744\ \(0\)\
\-\ brain\\:\\ 0\\.04729618558280962\ \(0\)\
\-\ treated\\:\\ 0\\.04724542189377199\ \(0\)\
\-\ for\\:\\ 0\\.04599028423597385\ \(0\)\
\-\ appearance\\:\\ 0\\.045738142402931115\ \(0\)\
\-\ head\\:\\ 0\\.04524960409439827\ \(0\)\
\-\ lymphoma\\:\\ 0\\.045184354231481726\ \(0\)\
\-\ through\\:\\ 0\\.04516267522035483\ \(0\)\
\-\ two\\:\\ 0\\.04505480706718741\ \(0\)\
\-\ secondary\\:\\ 0\\.04496913804067401\ \(0\)\
\-\ old\\:\\ 0\\.04490801382123727\ \(0\)\
\-\ however\\:\\ 0\\.04490524646681287\ \(0\)\
\-\ enhancement\\:\\ 0\\.04366855377152688\ \(0\)\
\-\ lesions\\:\\ 0\\.04357210613798523\ \(0\)\
\-\ signal\\:\\ 0\\.0430076620134867\ \(0\)\
\-\ patients\\:\\ 0\\.042680147151174026\ \(0\)\
\-\ prior\\:\\ 0\\.04244852587217267\ \(0\)\
\-\ both\\:\\ 0\\.0423079689985486\ \(0\)\
\-\ over\\:\\ 0\\.04218618856280435\ \(0\)\
\-\ follow\\:\\ 0\\.04089967772291672\ \(0\)\
\-\ can\\:\\ 0\\.039813354161793914\ \(0\)\
\-\ woman\\:\\ 0\\.039512531991678576\ \(0\)\
\-\ most\\:\\ 0\\.03948423395891471\ \(0\)\
\-\ it\\:\\ 0\\.03883599440498401\ \(0\)\
\-\ demonstrates\\:\\ 0\\.03811547962068298\ \(0\)\
\-\ large\\:\\ 0\\.038013854901749675\ \(0\)\
\-\ had\\:\\ 0\\.03780044664547634\ \(0\)\
\-\ in\\:\\ 0\\.03774721161900711\ \(0\)\
\-\ lateral\\:\\ 0\\.03765184096112615\ \(0\)\
\-\ up\\:\\ 0\\.03752925879954744\ \(0\)\
\-\ multiple\\:\\ 0\\.037108905560888195\ \(0\)\
\-\ images\\:\\ 0\\.03509420489753759\ \(0\)\
\-\ has\\:\\ 0\\.03465449310259036\ \(0\)\
\-\ that\\:\\ 0\\.03292405809034683\ \(0\)\
\-\ disease\\:\\ 0\\.031846876169528526\ \(0\)\
\-\ from\\:\\ 0\\.03013172816848986\ \(0\)\
\-\ not\\:\\ 0\\.029951055677587882\ \(0\)\
\-\ history\\:\\ 0\\.028986136436370515\ \(0\)\
\-\ ct\\:\\ 0\\.02888382769818271\ \(0\)\
